Maze Therapeutics (NASDAQ:MAZE) Trading 6.4% Higher – Here’s What Happened

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) were up 6.4% during mid-day trading on Monday . The company traded as high as $12.88 and last traded at $12.77. Approximately 27,430 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 270,449 shares. The stock had previously closed at $12.00.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several research reports. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price target for the company. Leerink Partnrs upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Guggenheim began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price target on the stock. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Price Performance

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.